AOD9604

AOD9604 is an orally active, lipolytic peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the C-terminal end. Human trials show that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production.

Mechanism of action
AOD9604 appears to enhance lipolysis by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604.

Clinical data
In a 12 week randomised trial, subjects receiving AOD9604 lost, on average, 1.8kg more than those receiving placebo. Development of AOD9604 was halted following insignificant efficacy in a later 24 week trial.